CNR1 and obesity disorder: However, the first-in-class CB1 antagonist/inverse agonist, rimonabant, though demonstrating effectiveness for obesity treatment and smoking cessation, displayed certain adverse psychiatric side effects, including anxiety and depression, resulting in its eventual withdrawal from the European market (Christensen et al., 2007; Sam et al., 2011).